Safic-Alcan gains full ownership of Sichuan HuaFaMei Enterprise Co

Published: 4-Jul-2016
Ingredients Finance

Gains a foothold in Asia from which to expand in the region


Safic-Alcan, an international distributor of speciality chemicals, has completed the acquisition of Sichuan HuaFaMei Enterprise Co in China.

The full ownership follows Safic-Alcan's acquisition of 50% of the firm in 2006. The shareholder and acting President, Charles Hu, will remain in place and continue to manage the business.

Founded in 1997, Sichuan HuaFaMei Enterprise Co is affiliated to the Paris, France-based BimSiframGroup while also being member of the international distributor, Safic-Alcan. The company specialises in offering active pharmaceutical ingredients, intermediates, plant extracts, chemical raw materials, drug products as well as a wide range of active pharmaceutical ingredients (APIs).

Sichuan HuaFaMei Enterprise Co has developed an outstanding reputation in the distribution of products with guaranteed traceability from export and import to final distribution and the reliability of its sourcing procedures. The company has also a proven record of strong international customer relationships through its professional and dedicated teams.

The company employs 44 people in China and in 2015 reported €14m in revenues.

'Acquiring full ownership of Sichuan HuaFaMei Enterprise Co is part of our strategy to expand in Asia. This acquisition will give Safic-Alcan direct access to the multinational pharmaceutical companies that have located in China and the opportunity to build upon the existing infrastructure to have a foothold in Asia from which Safic-Alcan can expand throughout the region,' said Martial Lecat, CEO of Safinca, the holding company of Safic- Alcan Group.

  • Companies:
  • Safic Alcan
See more

You may also like

Ingredients

FrieslandCampina Ingredients debuts consumer-driven concepts at Vitafoods Europe

Read more
The company will exhibit its omega-3 ingredient, as well as its active gut health solution

Trending Articles

  1. CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
  2. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach
  3. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  4. Highly potent APIs: Hazards in classification and handling This variability and subjective nature of classification means that the OEL is best considered as a tool for site risk management teams
  5. Small molecules: big market opportunities The rapid rise of biologic drugs in recent years has been accompanied by a market narrative that suggests that innovation and new treatments will be fuelled by breakthroughs in this area, leading to a decline in the small molecule pipeline. This is far from true, notes Kevin Cook, Chief Executive Officer at Sterling Pharma Solutions; both are increasing and small molecule drugs continue to be a mainstay of many drug development portfolios

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Ingredients

FrieslandCampina Ingredients debuts consumer-driven concepts at Vitafoods Europe

The company will exhibit its omega-3 ingredient, as well as its active gut health solution
Drug Delivery

Adult vaccination programmes deliver significant socio-economic benefits, study finds

The study shows that adult immunisation programmes return 19x their initial investment, which could ease the pressure on health systems
Manufacturing

CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery

The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
Ingredients

Therapeutic: acoramidis for transthyretin amyloid cardiomyopathy

Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare progressive disease that results from genetic mutations or ageing; misfolded TTR protein accumulates as amyloid fibrils in the myocardium
Ingredients

Therapeutic: lutikizumab for hidradenitis suppurativa

Hidradenitis suppurativa (HS) — also known as acne inversa — is a chronic, recurrent and progressive inflammatory disease that leads to irreversible skin damage and disability
Ingredients

Olon: celebrating 10 years of daptomycin and doubled production capacity

Olon's Daptomycin celebrates its 10th anniversary, and in the very year that marks the first decade of production of this first in a new class of antibiotics that represented a breakthrough in the treatment of skin infections, the leading API supplier group announces the doubling of its production to meet and exceed global demand for the active ingredient
Regulatory

Policy vacuum risks UK becoming a medicines supply backwater

The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Subscribe now